Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.

doi:10.2459/JCM.0b013e3283232a45

Article

Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.

Journal of cardiovascular medicine (Hagerstown, Md.) - 1 Apr 2009

Gambarin Fabiana I, Favalli Valentina, Serio Alessandra, Regazzi Mario, Pasotti Michele, Klersy Catherine, Dore Roberto, Mannarino Savina, Viganò Mario, Odero Attilio, Amato Simona, Tavazzi Luigi, Arbustini Eloisa

Abstract excerpt

BACKGROUND: The major clinical problem of Marfan syndrome (MFS) is the aortic root aneurysm, with risk of dissection when the root diameter approximates 5 cm. In MFS, a key molecule, transforming growth factor-beta (TGF-beta), normally bound to the extracellular matrix, is free and activated. In an experimental setting, TGF-beta blockade prevents the aortic root structural damage and dilatation. The angiotensin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.

Abstract excerpt

Topics

Related research